Cost Analysis of Ertapenem Therapy for Urinary Tract Infections and Assessment of Its Suitability for Outpatient Parenteral Antibiotic Therapy Programme in Turkey
Journal Title: Mediterranean Journal of Infection, Microbes and Antimicrobials - Year 2017, Vol 6, Issue 1
Abstract
Introduction: The primary aim of this study was to evaluate whether there was a difference between outpatient parenteral antibiotic therapy (OPAT) and inpatient parenteral antibiotic therapy (IPAT) costs of ertapenem for urinary tract infections (UTI’s) due to extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacilli, and to discuss suitability of ertapenem for OPAT programme of Turkey for the near future. Materials and Methods: A total of 53 patients hospitalized with the diagnosis of UTI and treated with ertapenem were retrospectively evaluated. The cost of ertapenem treatment as IPAT was actual costs retrieved from the hospital records. The estimated cost of the same antibiotic for the same patients as an OPAT programme was then calculated and the costs were compared. Results: The cost difference between IPAT and OPAT was ₺ 12.305 (€ 5783). Outpatient parenteral antibiotic therapy programme would provide an estimated 20% reduction in treatment costs. The estimated number of bed days saved, if the patients had received the treatment as OPAT, was calculated to be 583 days, which constitutes about 5% of the total number of hospitalization days. Conclusion: Applying ertapenem therapy through OPAT programme for UTIs caused by ESBL-producing Gram-negative bacilli will decrease the financial burden of health expenditures and the number of inpatient bed days in Turkey.
Authors and Affiliations
Bahar ÖRMEN, Nesrin TÜRKER, Nurbanu SEZAK, Zerrin KARA, Figen KAPTAN, Tuna DEMİRDAL, Melih Kaan SÖZMEN
Keywords
Related Articles
- EP ID EP689352
- DOI 10.4274/mjima.2017.7
- Views 139
- Downloads 0
Osteoarticular Candida Infection: Report of Three Cases and Literature Review of 44 Patients
Fungal infections in the bones and joints are rare. Candida spp. osteomyelitis is also a very rare entity. The most common pathogen is Candida albicans, but an increase in the incidence of non-albicans Candida osteomyeli...
Efficacy and Safety of the Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir Regimen for Chronic Hepatitis C in Hemodialysis Patients
Introduction: A higher percentage of sustained virologic response (SVR) has been reported with the introduction of direct-acting antivirals (DAAs) to the treatment of hepatitis C in recent years. However, there are still...
Recommendations for Intra-abdominal Infections “Consensus Report”
Guidelines include recommendations of experts from various specialties within a topic in consideration of data specific to each country. However, to date there has not been a guideline standardizing the nomenclature and...
Remarkable Antimicrobial Resistance in Nosocomial Spontaneous Bacterial Peritonitis
Introduction: The aim of this prospective observational study was to investigate the causative agents and their susceptibility to antimicrobial drugs in patients with nosocomial spontaneous bacterial peritonitis (SBP) in...
Evaluation of Nosocomial Infections after ABO-Compatible and Incompatible Liver Transplantations
Introduction: Liver transplantation is currently the only treatment option in acute hepatic failure and end-stage liver disease. In spite of their complications, ABO-incompatible liver transplantations are performed due...